UK start­up tack­les hot neoanti­gen field in can­cer drugs

Can­cer Re­search UK and the Na­tion­al In­sti­tute for Health Re­search have come to­geth­er to back a $17.5 mil­lion round for a new up­start en­ter­ing the in­creas­ing­ly hot neoanti­gen field.

The new biotech is called Achilles Ther­a­peu­tics, and it’s work­ing on de­vel­op­ing can­cer drugs based on the in­sights of sev­er­al ex­perts from top aca­d­e­m­ic groups in the coun­try. Their fo­cus is on trun­cal tu­mor neoanti­gens, with a spot­light on lung can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.